bioSyntagma awarded nearly $1M NSF grant
bioSyntagma, LLC, a precision medicine company, has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139, to continue development of technology that can isolate…